<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773964</url>
  </required_header>
  <id_info>
    <org_study_id>MET642-201</org_study_id>
    <nct_id>NCT04773964</nct_id>
  </id_info>
  <brief_title>Study to Evaluate MET642 in Patients With NASH</brief_title>
  <official_title>Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metacrine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metacrine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">February 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 28 days after last dose</time_frame>
    <description>Incidences of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Up to 28 days after last dose</time_frame>
    <description>Incidences of clinically significant changes in vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests</measure>
    <time_frame>Up to 28 days after last dose</time_frame>
    <description>Incidences of clinically significant changes in laboratory tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>Up to 28 days after last dose</time_frame>
    <description>Incidences of clinically significant changes in ECGs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of MET642</measure>
    <time_frame>16 weeks</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Profile of MET642</measure>
    <time_frame>16 weeks</time_frame>
    <description>C4 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacological Activity of MET642</measure>
    <time_frame>20 weeks</time_frame>
    <description>Measure of changes in liver fat using MRI-PDFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of MET642</measure>
    <time_frame>16 weeks</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of MET642</measure>
    <time_frame>16 weeks</time_frame>
    <description>T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of MET642</measure>
    <time_frame>16 weeks</time_frame>
    <description>AUC0-inf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Profile of MET642</measure>
    <time_frame>16 weeks</time_frame>
    <description>FGF19 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Profile of MET642</measure>
    <time_frame>16 weeks</time_frame>
    <description>Bile Acids concentrations</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>MET642 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MET642 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MET642 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MET642</intervention_name>
    <description>MET642 active treatment</description>
    <arm_group_label>MET642 high dose</arm_group_label>
    <arm_group_label>MET642 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>MET642 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of NASH via biopsy, magnetic resonance elastography (MRE), or transient&#xD;
             elastography (TE, FibroScan)&#xD;
&#xD;
          -  Liver fat content â‰¥ 10% as measured by magnetic resonance imaging-proton density fat&#xD;
             fraction (MRI-PDFF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant liver disease (eg, alcoholic liver disease, viral hepatitis,&#xD;
             etc.) or liver transplant.&#xD;
&#xD;
          -  Presence of cirrhosis on any prior liver biopsy (stage 4 fibrosis).&#xD;
&#xD;
          -  Excessive consumption of alcohol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pinnacle Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.metacrine.com</url>
    <description>Metacrine website</description>
  </link>
  <link>
    <url>http://www.nashfxr.com</url>
    <description>Study website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <keyword>Fatty Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

